Jiangsu Sinopep Allsino Biopharmaceutical Co.

What Jiangsu Sinopep Allsino Biopharmaceutical Co. does

Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. is a publicly listed Chinese Contract Development and Manufacturing Organization (CDMO) specializing in end-to-end CMC development and cGMP manufacturing of peptide and oligonucleotide active pharmaceutical ingredients (APIs), as well as small molecule intermediates and finished dosage forms. The company operates two main manufacturing sites — one in Hangzhou (headquarters, with the Apextide gene therapy/oligonucleotide operation) and one in Lianyungang (hosting the new Workshop 601 fourth-generation large-scale peptide facility and the new GMP oligonucleotide facility) — supported by three R&D centers. Established peptide capacity is 20–30 metric tons annually, with oligonucleotide capacity of thousands of kilograms per year; single-product annual capacity at Workshop 601 exceeds 5 tons with 10,000 liters of total reaction volume. The technology stack spans solid-phase and liquid-phase peptide synthesis, oligonucleotide synthesis (ASO, siRNA, miRNA, PMO, aptamer, CpG, decoy), peptide-oligo conjugates (POCs, PPMOs), proprietary high-concentration disulfide cyclization (50 mg/mL vs. ~20 mg/mL industry benchmark), in-house biocatalytic synthesis of non-canonical amino acids, and electrostatic spray drying integration.

The company serves global pharmaceutical and biotechnology innovators across three primary customer segments: (1) multinational pharma/biotech requiring end-to-end CDMO services from discovery through commercial supply, (2) generic drug manufacturers sourcing peptide/oligo/small molecule APIs (semaglutide, liraglutide, tirzepatide, orforglipron, inclisiran) backed by Type II Drug Master Files, and (3) early-stage drug discovery teams purchasing research-grade custom peptides and oligos. Revenue is generated through project-based contract manufacturing, generic API sales, and FTE/discovery services, all priced via quotation. Distribution is enterprise-direct via a USA Business Development team and global presence at major pharma industry conferences (CPHI, TIDES, DCAT Week, Boulder Peptide Symposium). The company is listed on the Shanghai Stock Exchange (688076.SH) and is led by Chairman Tong Ziquan and Senior Vice President Li Xiaohua; it holds wholly owned subsidiaries Apextide (oligonucleotides/gene therapy, established 2022) and Allsino Chemicals, plus a majority-controlled joint venture with Vazyme (688105.SH) for synthetic biology established in June 2025.

Name

Jiangsu Sinopep Allsino Biopharmaceutical Co.

Legal name

Sinopep-Allsino Biopharmaceutical Co., Ltd.

Website

https://sinopep.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sinopep-Allsino is a China-based, Shanghai-listed (688076.SH) peptide and oligonucleotide CDMO providing end-to-end CMC development and cGMP manufacturing (20–30 MT/year peptide capacity, thousands of kg/year oligonucleotide capacity) to global pharmaceutical innovators, generic API customers, and drug discovery teams.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO (Contract Development and Manufacturing)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)

Keywords

• Peptide CDMO services
• Oligonucleotide manufacturing
• GMP API production
• Pharmaceutical contract development
• Biopharmaceutical manufacturing

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Contract Manufacturing Services: Sinopep provides contract development and manufacturing services for peptide, oligonucleotide, and small molecule APIs and drug products. Services span from preclinical through commercial stages, including process development, analytical method development and validation, stability studies, and regulatory support for IND and NDA filings. Revenue is generated through project-based contracts with pharmaceutical companies.
2. Generic API Manufacturing: Sinopep develops and manufactures generic peptide, oligonucleotide, and small molecule APIs supported by active Type II Drug Master Files (DMFs) and Letters of Authorization, sold to pharmaceutical companies for further processing, R&D, or compounding.
3. Discovery Services: Custom research-grade peptide and oligonucleotide synthesis services for early-stage drug discovery, including pre-clinical custom peptides, peptide modifications, ASO, siRNA, miRNA, PMO, aptamer, CpG, decoy synthesis, and conjugate synthesis (POCs, PPMOs).

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Sinopep is a contract development and manufacturing organization (CDMO) providing end-to-end peptide, oligonucleotide, and small molecule API manufacturing. Its services span drug discovery, custom synthesis, CMC development, and commercial-scale cGMP production, including generic peptide APIs such as semaglutide, tirzepatide, and inclisiran. The company operates cGMP-compliant facilities with claimed industry-leading peptide production capacity.

Product overview

Sinopep is a Contract Development and Manufacturing Organization (CDMO) providing integrated peptide and oligonucleotide manufacturing services. The company operates a unified service platform comprising GMP Peptide CDMO Services and GMP Oligonucleotide Services as its core offerings, supplemented by Custom Peptide Synthesis, Custom Oligonucleotide Synthesis, Conjugate Synthesis Services (POCs and PPMOs), Generic APIs (including semaglutide, tirzepatide, orforglipron, and inclisiran), Formulation Services (oral solid dosage and lyophilized powder injections), Discovery Services, and FTE Services. The portfolio spans from early-stage discovery through commercial-scale GMP manufacturing with an annual peptide capacity of 20-30 metric tons.

Differentiator

Problem solved

Functional benefit

Products and services

• GMP Peptide CDMO Services End-to-end CMC development and commercial-scale cGMP manufacturing of peptide active pharmaceutical ingredients for pharmaceutical and biotechnology companies, from clinical through commercial supply.
• GMP Oligonucleotide Services Large-scale cGMP manufacturing of oligonucleotide APIs for pharmaceutical and biotechnology customers developing nucleic acid-based therapeutics.
• Custom Peptide Synthesis Custom synthesis of complex peptides for drug discovery and development, including peptides with disulfide bridges and non-canonical amino acids.
• Custom Oligonucleotide Synthesis Custom synthesis of oligonucleotides to support pharmaceutical research and development programs.
• Conjugate Synthesis Services Custom synthesis of peptide and oligonucleotide conjugates for pharmaceutical and biotechnology companies developing next-generation therapeutics.
• Generic Peptide APIs (Semaglutide, Tirzepatide, Inclisiran) Commercial supply of generic peptide active pharmaceutical ingredients including semaglutide, tirzepatide, and inclisiran for generic drug manufacturers and compounders.
• Small Molecule API Manufacturing cGMP-compliant small molecule API manufacturing provided as part of Sinopep's multi-modality CDMO platform.
• Formulation Services Drug product formulation services supporting peptide, oligonucleotide, and small molecule programs from development through commercial supply.
• Discovery Services Early-stage drug discovery services that complement the company's development and manufacturing offerings.
• FTE Services Full-Time Equivalent (FTE) resourcing services providing dedicated staff to support pharmaceutical and biotechnology development programs.

Quantifiable outcome

• Peptide API production capacity of 20-30 metric tons annually
• +6 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and strategic.

• Vazyme (688105.SH)coreStrategic or Co-development Partner · 20 June 2025Sinopep (688076.SH) and Vazyme (688105.SH) entered into a strategic partnership and established a joint venture (JV) to advance synthetic biology business development. Sinopep is majority-controlled in the JV. The collaboration marks Sinopep's expansion into synthetic biology technology platform, building upon its existing small molecule, peptide, and oligonucleotide technology platforms. Vazyme contributes over 600 types of genetically engineered recombinant enzymes and over 2,500 types of high-performance materials. The partnership targets industrial-scale production of complex natural products through biological methods.
• Spraying Systems Co.strategicTechnology or Integration · 10 December 2024SINOPEP entered into a strategic partnership with Spraying Systems Co., a global leader in industrial spray nozzle and automated spray system manufacturing founded in 1937 in Illinois, USA (with 12 production facilities and over 100 sales offices worldwide). The collaboration aims to integrate electrostatic spray drying technology into the commercial production of peptide and oligonucleotide APIs. Keith Cronce, Chief Operating Officer of Fluid Air (a division of Spraying Systems Co.), represented the company at the signing ceremony held at SINOPEP's Hangzhou headquarters.
• SK PharmtecocoreChannel Partner/ Reseller/ Distributor · 2 November 2022Allsino Chemicals Co. Ltd (a 100% subsidiary of Sinopep-Allsino Biopharmaceutical Co., Ltd., stock code: 688076) was awarded SK Pharmteco's Preferred Partner award at CPHI Frankfurt 2022. SK Pharmteco is a U.S.-based CMO and holding company of South Korea's SK Group (including SK Biotech, AMPAC Fine Chemicals, AMPAC Analytical, and Yposkesi). The award recognizes Allsino as one of the best suppliers worldwide to SK Pharmteco. Nearly 100 suppliers were evaluated, 10 were awarded, and Allsino was the only Chinese company selected.

Scale indicators11 records

Recent moves3 records

Expansion highlights6 records

Direct peers

• AmbioPharm: AmbioPharm is a U.S.-based peptide CDMO with commercial-scale manufacturing capabilities. Comparable to Sinopep in custom peptide synthesis and GMP peptide API production for global pharma customers, including generic peptide APIs.
• Bachem: Bachem is the world's largest independent peptide CDMO, providing GMP peptide API manufacturing from development through commercial supply. Directly comparable to Sinopep's core peptide CDMO business with similar end-to-end capabilities and global pharma customer base.
• CordenPharma: CordenPharma is a European full-service CDMO with strong peptide and oligonucleotide manufacturing capabilities. Directly comparable to Sinopep in integrated peptide/oligo API services, formulation, and regulatory support across the full NCE lifecycle.
• Asymchem Laboratories: Asymchem is a leading Chinese CDMO specializing in small molecule APIs and peptides with commercial-scale cGMP manufacturing. It is the closest direct peer to Sinopep in peptide CDMO with global regulatory inspections (FDA, EMA) and serves similar innovator and generic pharma customers.
• PolyPeptide Group: PolyPeptide Group is a Swiss-listed peptide CDMO offering custom synthesis and GMP manufacturing for peptide APIs and conjugates. Closely comparable to Sinopep's peptide CDMO service lines, particularly for NCE development and commercial peptide supply.

Emerging players

• Syngene International: Syngene is an Indian CRO/CDMO expanding into peptide and oligonucleotide manufacturing for global pharma. Emerging peer to Sinopep in API manufacturing services with comparable customer base of Western pharma innovators; benefits from India-based cost structure as Western buyers diversify away from China.
• Aurigene Pharmaceutical Services: Aurigene Pharmaceutical Services is an Indian CDMO providing small molecule and peptide API development and manufacturing. Emerging peer to Sinopep in peptide CDMO services, with growing capacity in oligonucleotide and complex peptide manufacturing targeting Western pharma customers.

Broad incumbents

• Lonza: Lonza is one of the world's largest CDMOs with broad capabilities across small molecules, biologics, and emerging modalities including peptides and oligonucleotides. Comparable to Sinopep as a commercial-scale API manufacturer with global regulatory reach, though Lonza operates across a much wider technology and modality portfolio.
• WuXi STA (WuXi AppTec): WuXi STA is the largest Chinese CDMO offering end-to-end small molecule, peptide, and oligonucleotide manufacturing services. Direct overlap with Sinopep in commercial-scale peptide and oligo API CDMO services for global pharma innovators, though WuXi operates at significantly larger scale across a broader modality portfolio.
• SK Pharmteco: SK Pharmteco is a global CMO/CDMO offering peptide, oligonucleotide, and small molecule API manufacturing through its subsidiaries (SK Biotech, AMPAC, Yposkesi). Comparable to Sinopep in peptide and small molecule CDMO services; notably recognized Sinopep subsidiary Allsino as a preferred partner at CPHI Frankfurt 2022.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Sinopep
• LinkedInlinkedin.com/company/sinopep-jiangsu-inc-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jiangsu Sinopep Allsino Biopharmaceutical Co.